Skip to main content
← All trials
Keratinocyte CarcinomaAestheticLooksmaxxingDrugDevicePhase 1, Phase 2

What this study is

The investigators seek to evaluate the effectiveness of fractional laser therapy and tirbanibulin ointment to treat squamous and basal cell carcinomas. This will be executed by using both thulium and erbium lasers on previously biopsy-confirmed SCCs and BCCs and applying bulk heating methods. Then, depending on the level of invasiveness, subjects may be instructed to apply the ointment over the course of five nights immediately following the treatment. The intention of this study is to minimize the need for invasive surgical procedures so as to optimize the cosmetic appearance, and provide a treatment option that is beneficial for a wide range of individuals.

What's being tested

  • Tirbanibulin ointment 1%

    Intervention · DRUG

    Tirbanibulin ointment is applied for 5 nights following the in-office fractional laser procedure for patients with more advanced carcinomas.

  • non-ablative fractional laser

    Intervention · DEVICE

    Every skin cancer will be treated with two wavelengths (1550nm and 1927nm) of a non-ablative fractional laser.

Study details

Official title
Using Fractional Lasers and Tirbanibulin Ointment to Treat Keratinocyte Carcinomas
Sponsor
Bruce Robinson, MD
Conditions
Keratinocyte Carcinoma · Basal Cell Carcinomas · Squamous Cell Carcinoma · Skin Cancer
Enrolling
100 people
Starts
2025-05-16
Est. completion
2030-06
Design
Open-label, non-randomized, factorial, Phase 1, Phase 2
Record
View on ClinicalTrials.gov ↗